%0 Journal Article
%A Novelli, Silvana
%A Bento, Leyre
%A Garcia, Irene
%A Prieto, Laura
%A Lopez, Lucia
%A Gutierrez, Gonzalo
%A Hernani, Rafael
%A Perez, Ariadna
%A Esquirol, Albert
%A Solano, Carlos
%A Bastos, Mariana
%A Dorado, Nieves
%A Rodriguez, Nancy
%A Rodriguez, Guillermo
%A Piñana, Jose L
%A Montoro, Juan
%A Herrera, Pilar
%A Luna, Alejandro
%A Parody, Rocio
%A Martín, Carmen
%A Garcia, Estefania
%A Lopez, Oriana
%A Heras, Inmaculada
%A Zanabili, Joud
%A Moraleda, Jose M
%A Yañez, Lucrecia
%A Gutierrez, Antonio
%A Zudaire, Teresa
%A Cordoba, Raul
%A Varela, Rosario
%A Ferra, Christelle
%A Martinez, Joaquin
%A Martinez, Carmen
%A Gonzalez-Barca, Eva
%A Martino, Rodrigo
%A Caballero, Dolores
%T Allogeneic Stem Cell Transplantation in Mature T Cell and Natural Killer/T Neoplasias: A Registry Study from Spanish GETH/GELTAMO Centers.
%D 2021
%U http://hdl.handle.net/10668/17585
%X Despite advances in understanding the biology of mature T and natural killer (NK)/T cell neoplasia, current therapies, even the most innovative ones, are still far from ensuring its cure. The only treatment to date that has been shown to control aggressive T cell neoplasms in the long term is allogeneic stem cell transplantation (alloSCT). We aim to report the results of alloSCT for advanced mature T and NK/T neoplasias performed in centers from our national GELTAMO/GETH (Grupo Español de Linfoma y Trasplante de Médula Ósea/Grupo Español de Trasplante Hematopoyético y Terapia Celular) over the past 25 years. As a secondary objective, we analyzed the results of alloSCT from haploidentical donors. We performed a retrospective analysis of all patients who received an alloSCT in Spanish centers (n = 201) from September 1995 to August 2018. The 2-year overall survival (OS) and disease-free survival (DFS) were 65.5% and 58.2%, respectively. The univariate for OS and DFS showed statistically different hazard ratios for conditioning intensity, response pre-alloSCT, comorbidity index, donor/receptor cytomegalovirus status and Eastern Cooperative Oncology Group (ECOG) pre-alloSCT, but only a better ECOG pre-alloSCT remained significant in the multivariate analysis. There was an increased incidence of relapse in those patients who did not develop chronic graft-versus-host disease (GVHD) and an increased risk of death in those developing moderate to severe acute GVHD. The 1-year nonrelapse mortality was 21.9% and was mainly due to GVHD (30%) and bacterial infections (17%). When comparing unrelated donors with haploidentical donors, we found similar results in terms of OS and DFS. There was, however, a reduction of acute GVHD in the haploidentical group (P = .04) and trend to a reduction of chronic GVHD. In conclusion, alloSCT is the only curative option for most aggressive T cell neoplasias. Haploidentical donors offer similar results to related donors in terms of survival with a reduction of acute GVHD.
%K Allogeneic stem cell transplantation
%K Haploidentical
%K T cell lymphoma
%~